GLP-1 receptor agonists (GLP-1RAs) — originally developed for type 2 diabetes and now dominant obesity pharmacotherapy — appear to improve male sexual and reproductive function through mechanisms well beyond caloric reduction. By reducing systemic inflammation, oxidative stress, and endothelial dysfunction, these drugs may reverse the hormonal cascades that obesity and metabolic syndrome impose on the hypothalamic-pituitary-gonadal axis, including functional hypogonadism and erectile dysfunction.
This finding lands at an important intersection. Obesity-driven hypogonadism — where excess adipose tissue converts testosterone to estradiol via aromatase while suppressing LH pulsatility — is notoriously difficult to treat without addressing underlying adiposity. GLP-1RAs like semaglutide and tirzepatide achieve 15–22% body weight reduction in clinical trials, which alone would be expected to elevate testosterone. But this review argues the drugs' anti-inflammatory and endothelial-protective properties contribute independently, a mechanistically plausible but still undervalidated claim. The critical limitation here is significant: this is a narrative review, not a systematic meta-analysis or original trial, making it inherently susceptible to selection bias and unable to establish causality or quantify effect sizes. No head-to-head comparisons between GLP-1RA classes on reproductive endpoints are available. For clinicians treating obese men with functional hypogonadism or ED, this synthesis is directionally useful — GLP-1RAs warrant consideration as first-line metabolic intervention before testosterone replacement. Confirmatory RCTs measuring hormonal and erectile outcomes as primary endpoints are urgently needed.
